If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Prosthetic valve selection should include criteria of patient age and suitability for anticoagulation, as well as patient preference, disease process, life expectancy, and future valve-in-valve options.
have presented their findings that prosthetic valve selection does not influence long-term survival in patients undergoing mitral valve replacement for ischemic mitral regurgitation; however, bioprosthetic valves appear to be associated with less morbidity. Guidelines on valve selection have generally cited patient age and suitability for lifelong anticoagulation, tempered by patient preference, as the dominant criteria for making recommendations. Evidence can be found to support bioprosthetic as well as mechanical valve use.
This trend initially was related to lifestyle preferences with respect to avoidance of anticoagulation, and until recently this included an acceptance of the possibility of an eventual conventional reoperation. Current trials with selected mechanical prostheses suggest the potential of lower anticoagulation requirements or possible alternative anticoagulation strategies. More recently, the potential for transcatheter valve-in-valve implantation has certainly entered the valve selection calculus as well.
Current valve selection guidelines do not discuss the evolution of transcatheter valve-in-valve therapies as a factor to be considered in primary prosthetic valve selection. Commentaries on this issue have raised concerns over valve size and gradients, uncertain longevity of transcatheter valves, and the potential need for subsequent procedures. Recently, a multicenter study of 1529 patients who underwent mitral valve-in-valve implantation demonstrated remarkable results in terms of technical success as well as 30-day and 1-year mortality.
the 10-year survival following mitral valve replacement for ischemic mitral regurgitation was <50%. At 15 years, only about 3% of patients had undergone reintervention. The reintervention rate was slightly higher in the mechanical valve group, although the bioprosthetic group was somewhat younger. This suggests that quality of life without management and potential complications of anticoagulation may be more germane considerations than mortality in valve selection for ischemic mitral regurgitation. This population is distinct from other valve replacement populations in that the pathology relates to ventricular ischemic dysfunction rather than a primary degenerative valvular issue. The understanding of this distinction has led to an evolution of treatment from annuloplasty remodeling to replacement.
The ischemic insult combined with ventricular dysfunction is undoubtedly a factor limiting patient survival. It may be that this limited survival potential negates the benefit of a mechanical prosthesis with increased durability.
Considering evolving bioprosthesis technology, with the potential of subsequent transcatheter approaches, it may be time to revise the guidelines to include consideration of valve-in-valve therapies into future strategies.
Prosthetic choice in mitral valve replacement for severe chronic ischemic mitral regurgitation: long-term follow-up.
Disclosures: Dr Accola is a consultant and speaker for Edwards Lifesciences. The other author reported no conflicts of interest.
The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
Prosthetic choice for mitral valve replacement is generally driven by patient age and patient and surgeon preference, and current guidelines do not discriminate between different etiologies of mitral valve disease. Our objective was to assess and compare short- and long-term outcomes after mitral valve replacement among patients with biological or mechanical prostheses in the setting of severe ischemic mitral regurgitation.